Sensitivity analysis 5 (excluding solanezumab, bapineuzumab, and aducanumab). Forest plot for efficacy outcomes.
journal contribution
posted on 2025-03-31, 17:44 authored by Reina Tonegawa-Kuji, Yuan Hou, Bo Hu, Noah Lorincz-Comi, Andrew A. Pieper, Babak Tousi, James B. Leverenz, Feixiong Cheng(a) The Clinical Dementia Rating-Sum of Boxes (CDR-SB) and (b) Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog).
(PDF)
History
Usage metrics
Keywords
related imaging abnormalitiesraises potential concernswide confidence intervalsmild cognitive impairmentimproving cognitive functionalzheimer &# 8217small effect sizesad assessment scaleregression analysis suggestedanalysis 01 ]), ariaxlink "> antitrials enrolling patientsci [&# 8722xlink ">effect sizes[&# 8722&# 8722confidence intervalcognitive subscalecognitive outcomes57 ]),06 ]),&# 946systematic reviewstudy presentsstatistical heterogeneitystage adside effectssecondary outcomesrisk ratioretrieved studiesrelatively highregression analysesrecently upublication biasprimary outcomespatients sufferingmean changesjanuary 15thjanuary 14thjadad scoreincluding amyloidincluded studiesfunnel plotfebruary 14thelevated riskdementia dueconsiderable variabilityassessed usingapproved antiamyloid betaadverse eventsad ),826 patients11 ])
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC